Milk thistle at a glance
Milk thistle (Silybum marianum) is a plant whose fruit contains silymarin, a mix of compounds led by silybin. Extracts of the fruit are standardised to a share of silymarin, such as 80% on the Hammer Labz labels below. Most trials were run in people with liver disease, and two Cochrane reviews found that evidence mostly of low quality. We found no trial of its effect on performance or recovery in healthy people who train. In the EU, milk thistle fruit is recognised as a traditional herbal medicine, on the basis of long-standing use.
Evidence: Human trials, in people with liver disease · Updated 20 November 2026
What milk thistle is
Milk thistle is the plant Silybum marianum, also known by the older name Carduus marianus. EU herbal medicines use its dried fruit, which is also the source of silymarin. Preparations of the fruit include the powder and extracts made with a solvent such as acetone, ethanol, ethyl acetate or methanol.
The fruit contains about 1.5 to 3% silymarin. Silymarin is not one compound but a mixture of flavonolignans. Silybin, also called silibinin, makes up 50 to 60% of it, silychristin about 20%, silydianin about 10% and isosilybin about 5%.
Extracts concentrate these compounds. A label such as “std. to 80% silymarin” states the silymarin share of the extract. In a label line such as “milk thistle (std. to 80% silymarin) 300 mg”, the 300 mg is the weight of the extract.
How it works
In laboratory studies, silymarin and its compounds act as antioxidants. In animal models of liver injury, milk thistle extract reduced collagen build-up in the liver and showed anti-inflammatory and antifibrotic effects. The EMA’s herbal committee says these findings could add to the plausibility of a benefit.
Absorption is the weak point. Silymarin dissolves poorly in water, and the EMA’s assessment report sums up that absorption after oral intake is low, with blood levels peaking after 4 to 6 hours. Between 20 and 40% of a dose is excreted in bile as conjugates. In one study, silybin bound to phosphatidylcholine reached the bile at several times the level of standard silymarin.
Liver disease changes the picture. In a small study, 20 people took the same single dose of extract. Exposure to silymarin compounds was 2.4 to 4.7 times higher in those with liver disease than in healthy volunteers.
Evidence
Evidence label: Human trials, in people with liver disease. Our labels describe the ingredient, not a product; see how we review.
Alcohol-related and viral liver disease. A 2007 Cochrane review pooled 18 randomised trials with 1,088 patients with alcoholic liver disease or hepatitis B or C. Only 28.6% of the trials reported high methodological quality. Milk thistle did not significantly change overall mortality, complications of liver disease or liver histology. Liver-related mortality fell when all trials were pooled, but not in the high-quality trials.
Hepatitis C. A US trial enrolled 154 people with chronic hepatitis C whose interferon treatment had failed. They took 420 mg or 700 mg of silymarin, or placebo, three times a day for 24 weeks. Two people in each group reached the target level of the liver enzyme ALT. ALT, viral load and quality of life did not differ between the groups.
Fatty liver disease. A 2025 Cochrane review covered 17 trials with 2,069 adults with metabolic dysfunction-associated steatotic liver disease (MASLD). Against placebo or no treatment, silymarin alone may lower ALT by about 7 U/L (6 trials, 409 people), but the evidence is very uncertain. Silymarin in complexes, for example with vitamin E or phosphatidylcholine, showed no clear effect on liver enzymes.
The EMA’s herbal committee reached a similar view in 2018. Studies in patients with liver disorders suggested a benefit, but firm conclusions could not be drawn because of poor design, small numbers and differing doses and treatment times.
Healthy people who train. We found no trial of milk thistle or silymarin measuring exercise performance or recovery in healthy people. One small trial in healthy male half-marathon runners measured markers of exercise-induced oxidative stress (PubMed search, 20 November 2026). Results from patients are not results for a supplement taken by a healthy person, not least because silymarin reaches different blood levels in liver disease.
What is in the capsule. A 2019 study analysed 26 milk thistle supplements bought in the US and the Czech Republic in 2016–2017. Silymarin content varied widely between products, often in contrast with what the makers stated, and between batches of the same product. Mycotoxins were found in all of them, and the authors also reported pesticide residues and microbial contamination.
Use with care. The EMA lists mild gut symptoms (dry mouth, nausea, upset stomach, diarrhoea), headache and allergic reactions, with unknown frequency. Milk thistle medicines must not be used by people allergic to plants of the daisy family (Asteraceae). The EMA does not recommend them in pregnancy or breastfeeding, and says their use in under-18s has not been established. In the 2007 Cochrane review, adverse events were not significantly more common with milk thistle than without. The monograph advises seeing a doctor straight away if the skin or eyes turn yellow or urine or stool changes colour.
Amounts on labels
| Hammer Labz product | As written on the label | Amount | Label serving |
|---|---|---|---|
| Liver Shield Pro | Milk thistle (std. to 80% silymarin) | 300 mg | 3 capsules |
| Liver Shield | Milk thistle (80% extract) | 300 mg | 3 capsules |
| Vita Shield | Silymarin (std. 80%) | 350 mg | 3 capsules |
Liver Shield Pro’s 300 mg is the weight of an extract standardised to 80% silymarin, not the weight of silymarin itself. Liver Shield gives “80% extract” without naming silymarin, so its label does not say what the 80% refers to. The Vita Shield label does not make clear whether its 350 mg is the extract or the silymarin. Vita Shield is a multivitamin, and its panel also lists zinc.
The hepatitis C trial used 420 or 700 mg of silymarin three times a day, amounts its authors describe as higher than customary.
Legal and anti-doping status
Status checked on 20 November 2026.
- EU, food: in the EU novel food catalogue, an acetone extract of milk thistle fruit with 70 to 80% silymarin is not novel in food supplements. The same applies to the plant’s aerial parts. Milk thistle seed oil is listed as not novel in food. The Hammer Labz labels do not state how their extracts were made.
- EU, herbal medicines: the EMA’s herbal committee (HMPC) adopted an EU herbal monograph on milk thistle fruit in 2018. The monograph covers traditional use only, for digestive complaints and liver function, after a doctor has ruled out serious disease. It adds that this indication is “exclusively based upon long-standing use”, and it covers herbal medicines, not food supplements. Traditional use means that evidence from clinical trials is insufficient but the effect is plausible. The medicine must also have been used in this way for at least 30 years, 15 of them in the EU.
- EU, medicines: single-ingredient medicines with milk thistle extract, silymarin or silibinin are authorised in 16 EU countries, Legalon among them, according to the EMA’s database (data file of 12 November 2026). That status applies to those medicines, not to food supplements.
- EU health claims: the EU list of permitted health claims (Regulation 432/2012) contains no claim for milk thistle or silymarin.
- WADA: milk thistle and silymarin are not named on the 2026 or 2027 WADA Prohibited List.
Status differs by country and changes over time.
Found in
Hammer Labz (brand page)
- Liver Shield Pro
- Liver Shield
- Vita Shield (multivitamin)
Haya Labs
- Milk Thistle 100 mg (60 capsules)
BioTech USA
- Liver Aid
We have not seen the labels of the other brands, so we give no amounts. For Liver Aid, a multi-ingredient formula, we confirmed milk thistle fruit extract in the ingredient list its maker publishes.
Sources
- Product labels: Hammer Labz supplement facts panels for Liver Shield Pro, Liver Shield and Vita Shield, as listed in November 2026.
- European Medicines Agency, Committee on Herbal Medicinal Products (2018). European Union herbal monograph on Silybum marianum (L.) Gaertn., fructus. EMA/HMPC/294187/2013, final, 5 June 2018. Accessed 20 November 2026.
- European Medicines Agency, Committee on Herbal Medicinal Products (2018). Assessment report on Silybum marianum (L.) Gaertn., fructus. Final, published 19 September 2018. Accessed 20 November 2026.
- European Medicines Agency. Silybi mariani fructus. Herbal medicine page with summary for the public (EMA/415131/2018). Accessed 20 November 2026.
- Rambaldi A, Jacobs BP, Gluud C (2007). Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev, 2007(4), CD003620. PMID: 17943794.
- Fried MW, Navarro VJ, Afdhal N, et al. (2012). Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA, 308(3), 274–282. PMID: 22797645.
- Wang C, Shang Y, Kanaan G, et al. (2025). Silymarin for adults with metabolic dysfunction-associated steatotic liver disease. Cochrane Database Syst Rev, 6(6), CD015524. PMID: 40552569.
- Boukazoula F, Ayari D (2022). Effect of milk thistle (Silybum marianum) supplementation on the serum levels of oxidative stress markers in male half marathon athletes. Biomarkers, 27(5), 461–469. PMID: 35315713.
- Fenclova M, Novakova A, Viktorova J, et al. (2019). Poor chemical and microbiological quality of the commercial milk thistle-based dietary supplements may account for their reported unsatisfactory and non-reproducible clinical outcomes. Sci Rep, 9(1), 11118. PMID: 31366891.
- European Commission. EU Novel Food status catalogue, entry “Silybum marianum”. Last modified 4 October 2024. Accessed 20 November 2026.
- European Medicines Agency. Article 57 product data: medicines authorised in the EU and EEA. Data file updated 12 November 2026. Accessed 20 November 2026.
- European Union. Commission Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods. Consolidated text of 20 August 2025. Accessed 20 November 2026.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 20 November 2026.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 20 November 2026.
- BioTechUSA. Liver Aid – 60 tablets. Product page. Accessed 20 November 2026.
